Portal de investigação
Nanostructured lipid carriers for enhanced batimastat delivery across the blood-brain barrier: an in vitro study for glioblastoma treatment
Autores da FMUP
Participantes de fora da FMUP
- Horta, M
- Sarmento, B
- Pereira, CL
- Lima, RT
Unidades de investigação
Abstract
Glioblastoma presents a significant treatment challenge due to the blood-brain barrier (BBB) hindering drug delivery, and the overexpression of matrix metalloproteinases (MMPs), which promotes tumor invasiveness. This study introduces a novel nanostructured lipid carrier (NLC) system designed for the delivery of batimastat, an MMP inhibitor, across the BBB and into the glioblastoma microenvironment. The NLCs were functionalized with epidermal growth factor (EGF) and a transferrin receptor-targeting construct to enhance BBB penetration and entrapment within the tumor microenvironment. NLCs were prepared by ultrasonicator-assisted hot homogenization, followed by surface functionalization with EGF and the construct though carbodiimide chemistry. The construct was successfully conjugated with an efficiency of 81%. Two functionalized NLC formulations, fMbat and fNbat, differing in the surfactant amount, were characterized. fMbat had a size of 302 nm, a polydispersity index (PDI) of 0.298, a zeta-potential (ZP) of -27.1 mV and an 85% functionalization efficiency (%FE), whereas fNbat measured 285 nm, with a PDI of 0.249, a ZP of -28.6 mV and a %FE of 92%. Both formulations achieved a drug loading of 0.42 mu g/mg. In vitro assays showed that fNbat was cytotoxic and failed to cross the BBB, while fMbat showed cytocompatibility at concentrations 10 times higher than the drug's IC50. Additionally, fMbat inhibited MMP-2 activity between 11 and 62% across different cell lines and achieved a three-fold increase in BBB penetration upon functionalization. Our results suggest that the fMbat formulation has potential for enhancing GB treatment by overcoming current drug delivery limitations and may be combined with other therapeutic strategies for improved outcomes.
Dados da publicação
- ISSN/ISSNe:
- 2190-3948, 2190-393X
- Tipo:
- Article
- Páginas:
- -
- Link para outro recurso:
- www.scopus.com
Drug Delivery and Translational Research Springer Publishing Company
Documentos
- Não há documentos
Filiações
Keywords
- Nanostructured Lipid Carrier; Glioblastoma; Batimastat; Extracellular Matrix
Financiamento
Proyectos asociados
Selenium Clinical Supplementation In Autoimmune Thyroid Disease: A Portuguese Survey
Investigador Principal: Ana Paula Soares Dias Ferreira
Estudo Clínico Académico . 2022
Squamous cell carcinogenesis of the skin: Molecular characterization of prognostic therapeutic biomakers
Investigador Principal: Ana Paula Soares Dias Ferreira
Estudo Clínico Académico . 2022
Clinicopathological features and molecular biomarkers? role predicting papillary thyroid cancer patients? outcome: How to personalize and guide surgical treatment
Investigador Principal: Ana Paula Soares Dias Ferreira
Estudo Clínico Académico . 2022
Fatores do microambiente tumoral no cancro do ovário.
Investigador Principal: Ana Paula Soares Dias Ferreira
Estudo Clínico Académico . 2022
Citar a publicação
Horta M,Soares P,Sarmento B,Pereira CL,Lima RT. Nanostructured lipid carriers for enhanced batimastat delivery across the blood-brain barrier: an in vitro study for glioblastoma treatment. Drug Deliv. Transl. Res. 2025. a020412. IF:5,400. (1).
